FPIN's Help Desk Answers

Reducing Amputation Rates After Severe Frostbite

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2015 Oct 15;92(8):716.

Clinical Question

Is tissue plasminogen activator (tPA) effective in reducing digital amputation rates in patients with severe frostbite?

Evidence-Based Answer

In patients with severe frostbite, tPA plus a prostacyclin may be used to decrease the risk of digital amputation. (Strength of Recommendation [SOR]: B, based on a single randomized controlled trial [RCT].) tPA can be used alone and is associated with lower amputation rates compared with local wound care. (SOR: C, based on lower-quality cohort studies.)

A 2011, open-label RCT (n = 47) compared tPA plus iloprost (Ventavis), iloprost alone, and buflomedil (not available in the United States) in patients with frostbite extending just past the proximal phalanx or injury proximal to the metacarpal or metatarsal joint.1 Digital perfusion was not assessed before treatment. All patients underwent rapid tissue rewarming and received 250 mg of aspirin and 400 mg of intravenous (IV) buflomedil. Patients then received 100 mg of IV tPA plus an IV infusion of iloprost (0.5 to 2 ng per kg per minute) for six hours per day, iloprost alone, or 400 mg of IV buflomedil per day. After eight days, a technetium-99m scan was used to identify digits at risk of amputation. In the buflomedil group, nine of 15 patients were at risk of amputation compared with zero of 16 in the iloprost group (P < .001) and three of 16 in the tPA plus iloprost group (P < .03). After three months, four patients in the iloprost group had amputations compared with three in the tPA plus iloprost group. Statistical testing between the tPA plus iloprost and the iloprost alone groups was not reported, and comparisons between groups were complicated by unbalanced randomization; there were 25 digits in the tPA plus iloprost group with severe disease and only three and nine digits in the other treatment arms. Thus, no conclusions can be reached about the effect of tPA plus iloprost compared with iloprost alone.

A 2007 retrospective cohort trial evaluated the use of tPA in six patients with severe frostbite.2 After rapid rewarming, patients underwent digital angiography, and those with significant perfusion defects received intraarterial tPA (0.5 to 1 mg per hour IV infusion) and heparin (500 units per hour IV infusion) for up to 48 hours. Patients who presented after 24 hours and had normal or uninterpretable angiography results (n = 26) received local wound care. The tPA group had a lower amputation rate (10% vs. 41%; P < .05), but patients in the control group were not matched for injury severity.

A 2005 prospective cohort trial evaluated the use of tPA in 19 patients with severe frostbite (no perfusion on technetium-99m bone scan).3 In patients who received intra-arterial or IV tPA, 33 of 174 affected digits (19%) were amputated. In eight historical control patients who had undergone local wound care alone, at least 60 of 65 affected digits (92%) were amputated.

Address correspondence to Jennifer Taves, MD, at jennifer.taves@centracare.com. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

1. Cauchy E, et al. A controlled trial of a prostacyclin and rt-PA in the treatment of severe frostbite. N Engl J Med. 2011;364(2):189–190.

2. Bruen KJ, et al. Reduction of the incidence of amputation in frostbite injury with thrombolytic therapy. Arch Surg. 2007;142(6):546–551.

3. Twomey JA, et al. An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite. J Trauma. 2005;59(6):1350–1354.

Help Desk Answers provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review.

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or email: questions@fpin.org.

This series is coordinated by John E. Delzell, Jr., MD, MSPH, Assistant Medical Editor.

Copyright Family Physicians Inquiries Network. Used with permission.



 

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article